Early markers of cognitive enhancement: developing an implicit measure of cognitive performance
- 881 Downloads
There is intense interest in the development of effective cognitive enhancing drugs which would have therapeutic application across a number of neurological and psychological disorders including dementia, schizophrenia and depression. However, development in this area has been limited by the absence of sensitive biomarkers which can be used to detect and refine therapeutic-like action in phase 1 clinical studies. The aim of the present study was therefore to develop a measure of cognition relevant to the action of candidate cognitive enhancers which might be sensitive to pharmacological manipulation in healthy volunteers. Healthy volunteers (n = 34) were randomised to receive a single dose of modafinil (100 mg) or placebo. Five hours post dose, attentional flexibility in learning was assessed using a novel implicit learning task. Volunteers also completed an auditory digit span task and visual analogue scales (VAS). Modafinil increased alertness as measured by the VAS. In the implicit learning task, modafinil enhanced learning rates in terms of both accuracy and reaction time, suggesting an increase in implicit rule learning. These results suggest that the novel learning task should be explored as a biomarker of early cognitive improvement which could be more sensitive than conventional measures.
KeywordsCognitive enhancement Modafinil Set shifting
Conflicts of interest
CJH has acted as a consultant for the following companies: Servier, GSK, Astra-Zeneca. Lundbeck and P1vital. She also holds shares in P1vital and is on the advisory board. PJC has been a paid member of advisory boards of Eli Lilly, Lundbeck, Servier and Wyeth and has been a paid lecturer for Eli Lilly, Lundbeck, GlaxoSmithKline and Servier. He has received remuneration for scientific advice given to legal representatives of GlaxoSmithKline. AP, EP and MB report no conflicts of interest.
- Cleeremans A (2006) Conscious and unconscious cognition: a graded dynamic perspective. Psychology Press, HoveGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview for axis I and II DSM-IV disorders: patient edition (SCID-IV/P). Biometrics Research Department, New YorkGoogle Scholar
- Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, Lopez-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW (2009) Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res 115:104–114PubMedCrossRefGoogle Scholar
- Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141–168PubMedCrossRefGoogle Scholar
- Nelson HE (1982) National Adult Reading Test (NART): test manual. NFER-Nelson, WindsorGoogle Scholar
- Spielberger CD, Gorsuch RL, Lushene RD (1970) STAI manual. Consulting Psychologists Press, Palo AltoGoogle Scholar
- Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165:260–269Google Scholar
- von Zerseen D, Strian F, Schwarz D (1974) Evaluation of depressive states, especially in longitudinal studies. In: Pichot B (ed) Psychological measurements in psychopharmacology. Karger, BaselGoogle Scholar